Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Holtzman

Showing results (551-560 of 554) with videos related to

Pageof 56
Sort By:
You have reached the last page of results.This site can display upto 554 results.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 26, 2011
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkersNiklas Mattsson, Ulf Andreasson, Staffan Persson, et al.
Nature Communications|April 21, 2026
GWAS meta-analysis of cerebrospinal fluid Alzheimer's biomarkers reveals loci regulating lipids, brain volume and autophagyJigyasha Timsina, Chenyang Jiang, Daniel L McCartney, et al.
Pageof 56

Showing results (551-560 of 554) with videos related to

Sort By:
Pageof 56
You have reached the last page of results.This site can display upto 554 results.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 26, 2011
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkersNiklas Mattsson, Ulf Andreasson, Staffan Persson, et al.
Nature Communications|April 21, 2026
GWAS meta-analysis of cerebrospinal fluid Alzheimer's biomarkers reveals loci regulating lipids, brain volume and autophagyJigyasha Timsina, Chenyang Jiang, Daniel L McCartney, et al.
Pageof 56